Biblio

Author Title Type [ Year

]

Filters: Author is Inaba, Hiroto [Clear All Filters]

2013

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, W Bowman P, Taub JW, Pui C-H, Ribeiro RC, Coustan-Smith E, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer. 2013.

2014

Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, Inaba H, Bhojwani D, Metzger ML, Cheng C, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2014.

2019

Orgel E, Alexander TB, Wood BL, Kahwash SB, Devidas M, Dai Y, Alonzo TA, Mullighan CG, Inaba H, Hunger SP, et al. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2019.

2020

Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(1):81-112.